Clinical Scorecard: Efficacy, immune response, and safety profile of COVID-19 vaccines in patients with hematological cancers: a systematic analysis

At a Glance

Key Highlights

• Patients with hematological malignancies have higher risk of severe COVID-19 and complications due to immune dysfunction.
• COVID-19 vaccines show impaired immunogenicity in HM patients, with reduced humoral and cellular responses compared to immunocompetent individuals.
• Booster vaccinations and variant-adapted vaccines are critical to improve protection in this vulnerable population.

Guideline-Based Recommendations

Diagnosis

• Identify patients with hematological malignancies as high-risk for severe COVID-19 infection.
• Assess immune status considering disease and treatment-related immunodeficiency.

Management

• Administer full primary COVID-19 vaccination schedules authorized for use, including mRNA, vector-based, and inactivated vaccines.
• Consider booster doses ≥3 months after primary immunization to enhance immunity.
• Monitor emerging data to optimize vaccination schedules tailored to HM patients.

Monitoring & Follow-up

• Evaluate seroconversion and immunoglobulin G titers post-vaccination.
• Assess neutralizing antibody activity and T-cell responses where feasible.
• Monitor for adverse events including allergic reactions, thrombotic events, myocarditis, and malignancy progression.

Risks

• Reduced vaccine-induced immune protection due to underlying immune dysfunction.
• Potential for severe COVID-19 despite vaccination in HM patients.
• Adverse events related to vaccination require careful surveillance.

Patient & Prescribing Data

Adults with hematological malignancies receiving authorized COVID-19 vaccines

Vaccination induces lower immune responses compared to healthy controls; booster doses and variant-specific vaccines are important to improve protection.

Clinical Best Practices

• Prioritize COVID-19 vaccination in patients with hematological malignancies due to high risk of severe disease.
• Use authorized vaccines with full primary immunization schedules and timely booster doses.
• Incorporate immune monitoring to identify patients with suboptimal vaccine responses.
• Stay updated on evolving evidence regarding vaccine efficacy against SARS-CoV-2 variants in HM patients.
• Maintain vigilance for vaccine-related adverse events and manage accordingly.

References

• Systematic review protocol on Open Science Framework